LAB (Standard BioTools) YoY EPS Growth: 22.22% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LAB Standard BioTools Inc LAB
33 GF Score
Price $0.65
GF Value $0.71
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Standard BioTools YoY EPS Growth?

Standard BioTools LAB -3.39% 33 YoY EPS Growth is 22.22% as of Jun. 2026. GuruFocus rates LAB with a GF Score™ of 33/100 and a GF Value™ of $0.71 (Fairly Valued). The stock has 5 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Standard BioTools's YoY EPS Growth for the quarter that ended in Jun. 2026 was 22.22%.

Standard BioTools's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-0.07.

Standard BioTools YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Standard BioTools's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Standard BioTools YoY EPS Growth Chart

Standard BioTools Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.41 -211.54 61.32 44.68 61.54

Standard BioTools Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.00 -28.57 155.56 571.43 22.22
LAB
33GF Score
Standard BioTools Inc LAB
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Standard BioTools YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Standard BioTools's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-0.2--0.52)/ | -0.52 |
=61.54 %

Standard BioTools's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.07--0.09)/ | -0.09 |
=22.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 22.22% mean?
Standard BioTools (LAB) has a YoY EPS Growth of 22.22% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Standard BioTools and its competitors.
Is Standard BioTools' YoY EPS Growth too high?
Standard BioTools' current YoY EPS Growth is 22.22%. Overall, Standard BioTools has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' YoY EPS Growth compare to CV and ELMD?
Standard BioTools' YoY EPS Growth of 22.22% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Medical Devices & Instruments company?
A good YoY EPS Growth depends on the Medical Devices & Instruments industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Standard BioTools and its competitors. Standard BioTools's current YoY EPS Growth is 22.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (LAB) is currently considered Fairly Valued. The stock's GF Value™ is $0.71, compared to a current price of $0.65 — trading 8.6% below its estimated fair value. The current YoY EPS Growth is 22.22%. Standard BioTools' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Standard BioTools (LAB), the current YoY EPS Growth is 22.22% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Standard BioTools (LAB) Overvalued in 2026?

Based on GuruFocus' analysis, Standard BioTools stock appears to be undervalued. The current stock price of $0.65 is trading 8.6% below its estimated GF Value™ of $0.71. GuruFocus considers Standard BioTools to be Fairly Valued.

Key valuation signals for LAB:

  • YoY EPS Growth: 22.22%
  • GF Value™: $0.71 vs. price of $0.65 (8.6% below fair value)
  • GF Score™: 33/100 with 5 warning signs

No single metric tells the full story. See the LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Standard BioTools Business Description

Other Exchanges FLB:Germany
Address 50 Milk Street, 10th Floor, Boston, MA, USA, 02109
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
33GF Score

Get the complete analysis for LAB

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price
$0.71
GF Value